Use of an adrenal hormone-modifying agent

US8609862B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Qi Hu · Needham, US
• Gary Michael Ksander · Carmel, US
• Erik Meredith · Cambridge, US
• Lauren G. Monovich · Summit, US
• Julien Papillon · Cambridge, US
• Christoph Schumacher · Bettingen, CH

Key dates

• Filing date: Jan 13, 2011
• Grant date: Dec 17, 2013
• Expiry date: Jan 13, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I):wherein n is 1 or 3; R is hydrogen or —C(O)N(Ra)(Rb) wherein Ra and Rb are independently —(C1-C4)alkyl, or —(C1-C4)alkyl-(C5-C7)aryl, wherein each of Ra and Rb is optionally substituted by —(C1-C4)alkoxy; R1, R2, and R3, are independently hydrogen, halogen, cyano or —(C6-C10) aryl, wherein said —(C6-C10)aryl is optionally substituted by halogen, with the proviso that no more than one of R1, R2, and R3 is hydrogen; and R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.